The role of anti-inflammatory drugs in colorectal cancer

Annual Review of Medicine

Volumn 64, Issue , 2013, Pages 131-144

  Wang, Dingzhi ^a   DuBois, Raymond N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

chemoprevention; cyclooxygenase; nonsteroidal anti inflammatory drugs (NSAIDs); prostaglandins

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; ARACHIDONIC ACID; CANCER VACCINE; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN G; PROTON PUMP INHIBITOR; THROMBOXANE A2;

BLEEDING; CANCER GROWTH; CARDIOTOXICITY; COLORECTAL CANCER; DNA METHYLATION; DRUG EFFICACY; ENTERITIS; FAMILIAL COLON POLYPOSIS; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HUMAN; JUVENILE POLYPOSIS SYNDROME; NATURAL KILLER CELL; NONHUMAN; OBESITY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLORECTAL NEOPLASMS; HUMANS; MORBIDITY; PROGNOSIS; WORLD HEALTH;

EID: 84873026456     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-112211-154330     Document Type: Review

References (95)

1. Powell SM, Zilz N, Beazer-Barclay Y, et al. 1992. APC mutations occur early during colorectal tumorigenesis. Nature 359:235-37
2. Tarmin L, Yin J, Harpaz N, et al. 1995. Adenomatous polyposis coli gene mutations in ulcerative colitisassociated dysplasias and cancers versus sporadic colon neoplasms. Cancer Res. 55:2035-38
3. Feagins LA, Souza RF, Spechler SJ. 2009. Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nat. Rev. Gastroenterol. Hepatol. 6:297-305
4. Markowitz SD, Bertagnolli MM. 2009. Molecular origins of cancer: molecular basis of colorectal cancer. N. Engl. J. Med. 361:2449-60
5. Kondo Y, Issa JP. 2004. Epigenetic changes in colorectal cancer. Cancer Metastasis Rev. 23:29-39
6. Barault L, Charon-Barra C, Jooste V, et al. 2008. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res. 68:8541-46
7. Shen L, Toyota M, Kondo Y, et al. 2007. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc. Natl. Acad. Sci. USA 104:18654-59
8. Hinoue T, Weisenberger DJ, LangeCP, et al. 2012. Genome-scale analysis of aberrantDNAmethylation in colorectal cancer. Genome Res. 22:271-82
9. Chan AT, Giovannucci EL. 2010. Primary prevention of colorectal cancer. Gastroenterology 138:2029-43e10
10. Wang D, DuBois RN. 2010. Eicosanoids and cancer. Nat. Rev. Cancer 10:181-93
11. Newcomb PA, Baron J, Cotterchio M, et al. 2007. ColonCancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol. Biomarkers Prev. 16:2331-43
12. Eberhart CE, Coffey RJ, Radhika A, et al. 1994. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107:1183-88
13. Ogino S, Kirkner GJ, Nosho K, et al. 2008. Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin. Cancer Res. 14:8221-27
14. Singer II, Kawka DW, Schloemann S, et al. 1998. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 115:297-306
15. Waddell WR, Loughry RW. 1983. Sulindac for polyposis of the colon. J. Surg. Oncol. 24:83-87
16. Labayle D, Fischer D, Vielh P, et al. 1991. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101:635-39
17. Giardiello FM, Hamilton SR, Krush AJ, et al. 1993. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 328:1313-16
18. Rostom A, Dube C, Lewin G, et al. 2007. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann. Intern. Med. 146:376-89
19. Steinbach G, Lynch PM, Phillips RK, et al. 2000. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342:1946-52
20. Mangiantini F, Lorusso M, Pozzi E, et al. 2009. Efficacy of meloxicam in a patient with juvenile polyposis syndrome. J. Pediatr. Gastroenterol. Nutr. 48:636-38
21. Cuzick J, Otto F, Baron JA, et al. 2009. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 10:501-7
22. Burn J, Bishop DT, Chapman PD, et al. 2011. A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev. Res. (Phila.) 4:655-65
23. Burn J, GerdesAM, Macrae F, et al. 2011. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378:2081-87
24. Rothwell PM, Price JF, Fowkes FG, et al. 2012. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379:1602-12
25. Eaden J, Abrams K, Ekbom A, et al. 2000. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment. Pharmacol. Ther. 14:145-53
26. Moody GA, Jayanthi V, Probert CS, et al. 1996. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur. J. Gastroenterol. Hepatol. 8:1179-83
27. van Staa TP, Card T, Logan RF, Leufkens HG. 2005. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 54:1573-78
28. Rubin DT, LoSavio A, Yadron N, et al. 2006. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin. Gastroenterol. Hepatol. 4:1346-50
29. Pinczowski D, Ekbom A, Baron J, et al. 1994. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 107:117-20
30. Mahadevan U, Loftus EV Jr., Tremaine WJ, et al. 2002. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am. J. Gastroenterol. 97:910-14
31. El Miedany Y, Youssef S, Ahmed I, et al. 2006. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective COX-2 inhibitor in inflammatory bowel diseases. Am. J. Gastroenterol. 101:311-17
32. Eaden J. 2003. Review article: the data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 18(Suppl. 2):15-21
33. Bernstein CN, Eaden J, Steinhart AH, et al. 2002. Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid. Inflamm. Bowel Dis. 8:356-61
34. KhandekarMJ, Cohen P, Spiegelman BM. 2011. Molecular mechanisms of cancer development in obesity. Nat. Rev. Cancer 11:886-95
35. Sinicrope FA, Foster NR, Sargent DJ, et al. 2010. Obesity is an independent prognostic variable in colon cancer survivors. Clin. Cancer Res. 16:1884-93
36. Slattery ML, Curtin K, Sweeney C, et al. 2007. Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. Int. J. Cancer 120:656-63
37. Kim S, Baron JA, Mott LA, et al. 2006. Aspirin may be more effective in preventing colorectal adenomas in patients with higher BMI (United States). Cancer Causes Control. 17:1299-304
38. Zhang X, Smith-Warner SA, Chan AT, et al. 2011. Aspirin use, body mass index, physical activity, plasma C-peptide, and colon cancer risk in US health professionals. Am. J. Epidemiol. 174:459-67
39. Harris RE. 2009. Cyclooxygenase-2 (COX-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 17:55-67
40. Bertagnolli MM, Eagle CJ, Zauber AG, et al. 2006. Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med. 355:873-84
41. Arber N, Eagle CJ, Spicak J, et al. 2006. Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med. 355:885-95
42. Baron JA, Sandler RS, Bresalier RS, et al. 2006. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 131:1674-82
43. Bertagnolli MM, Eagle CJ, Zauber AG, et al. 2009. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev. Res. (Phila.) 2:310-21
44. Solomon SD, Wittes J, Finn PV, et al. 2008. Cardiovascular risk of celecoxib in 6 randomized placebocontrolled trials: the cross trial safety analysis. Circulation 117:2104-13
45. Chan AT, Sima CS, Zauber AG, et al. 2011. C-reactive protein and risk of colorectal adenoma according to celecoxib treatment. Cancer Prev. Res. (Phila.) 4:1172-80
46. Solomon SD, Pfeffer MA, McMurray JJ, et al. 2006. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 114:1028-35
47. Graham DJ, Campen D, Hui R, et al. 2005. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365:475-81
48. Din FV, Theodoratou E, Farrington SM, et al. 2010. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut 59:1670-79
49. Chan AT, Ogino S, Fuchs CS. 2007. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N. Engl. J. Med. 356:2131-42
50. Chan AT, Ogino S, Fuchs CS. 2009. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302:649-58
51. Algra AM, Rothwell PM. 2012. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 13:518-27
52. Logan RF, Grainge MJ, Shepherd VC, et al. 2008. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 134:29-38
53. Baron JA, Cole BF, Sandler RS, et al. 2003. A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. 348:891-99
54. Benamouzig R, Deyra J, Martin A, et al. 2003. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 125:328-36
55. Sandler RS, Halabi S, Baron JA, et al. 2003. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med. 348:883-90
56. Barry EL, Sansbury LB, Grau MV, et al. 2009. Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence-data from a randomized clinical trial. Cancer Epidemiol. Biomarkers Prev. 18:2726-33
57. Rothwell PM, Wilson M, Elwin CE, et al. 2010. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376:1741-50
58. Rothwell PM, Wilson M, Price JF, et al. 2012. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379:1591-601
59. Rigas B, Goldman IS, Levine L. 1993. Altered eicosanoid levels in human colon cancer. J. Lab. Clin.Med. 122:518-23
60. Cai Q, Gao YT, Chow WH, et al. 2006. Prospective study of urinary prostaglandin E2 metabolite and colorectal cancer risk. J. Clin. Oncol. 24:5010-16
61. Johnson JC, Schmidt CR, Shrubsole MJ, et al. 2006. Urine PGE-M: a metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia. Clin. Gastroenterol. Hepatol. 4:1358-65
62. Keller JJ, Offerhaus GJ, Polak M, et al. 1999. Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac. Gut 45:822-28
63. Sinicrope FA, Half E, Morris JS, et al. 2004. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. Cancer Epidemiol. Biomarkers Prev. 13:920-27
64. Tahara T, Shibata T, Yamashita H, et al. 2009. Chronic nonsteroidal anti-inflammatory drug (NSAID) use suppresses multiple CpG islands hyper methylation (CIHM) of tumor suppressor genes in the human gastric mucosa. Cancer Sci. 100:1192-97
65. Liu CH, Chang SH, Narko K, et al. 2001. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J. Biol. Chem. 276:18563-69
66. Colby JK, Klein RD, McArthur MJ, et al. 2008. Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression. Neoplasia 10:782-96
67. Xia D, Wang D, Katkuri S, et al. 2012. Prostaglandin E2 promotes intestinal tumor growth via DNA methylation. Nat. Med. 18:224-26
68. Pereira MA, Tao L, Wang W, et al. 2004. Modulation by celecoxib and difluoromethylornithine of the methylation of DNA and the estrogen receptor-alpha gene in rat colon tumors. Carcinogenesis 25:1917-23
69. Lee KH, Lee JS, Nam JH, et al. 2011. Promoter methylation status of hMLH1, hMSH2, and MGMTgenes in colorectal cancer associated with adenoma-carcinoma sequence. Langenbecks Arch. Surg. 396:1017-26
70. Herman JG, Umar A, Polyak K, et al. 1998. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA 95:6870-75
71. Zeytin HE, Patel AC, Rogers CJ, et al. 2004. Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice. Cancer Res. 64:3668-78
72. Basu GD, Tinder TL, Bradley JM, et al. 2006. Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J. Immunol. 177:2391-402
73. DeLong P, Tanaka T, Kruklitis R, et al. 2003. Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy. Cancer Res. 63:7845-52
74. Qian BZ, Pollard JW. 2010. Macrophage diversity enhances tumor progression and metastasis. Cell 141:39-51
75. Bacman D, Merkel S, Croner R, et al. 2007. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours showmore tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study. BMC Cancer 7:156-66
76. Mantovani A, Sozzani S, Locati M, et al. 2002. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23:549-55
77. Nakanishi Y, Nakatsuji M, Seno H, et al. 2011. COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in ApcMin/+ mouse polyps. Carcinogenesis 32:1333-39
78. Della PortaM, DanovaM, Rigolin GM, et al. 2005. Dendritic cells and vascular endothelial growth factor in colorectal cancer: correlations with clinicobiological findings. Oncology 68:276-84
79. Kim HJ, Lee YH, Im SA, et al. 2010. Cyclooxygenase inhibitors, aspirin and ibuprofen, inhibit MHCrestricted antigen presentation in dendritic cells. Immune Netw. 10:92-98
80. Kondo E, Koda K, Takiguchi N, et al. 2003. Preoperative natural killer cell activity as a prognostic factor for distant metastasis following surgery for colon cancer. Dig. Surg. 20:445-51
81. Kundu N, Walser TC, Ma X, et al. 2005. Cyclooxygenase inhibitors modulate NK activities that control metastatic disease. Cancer Immunol. Immunother. 54:981-87
82. Gabrilovich DI, Nagaraj S. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9:162-74
83. Huang B, Pan PY, Li Q, et al. 2006. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66:1123-31
84. Mandruzzato S, Solito S, Falisi E, et al. 2009. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J. Immunol. 182:6562-68
85. Diaz-MonteroCM, SalemML, NishimuraMI, et al. 2009. Increased circulatingmyeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 58:49-59
86. Talmadge JE, Hood KC, Zobel LC, et al. 2007. Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion. Int. Immunopharmacol. 7:140-51
87. Strauss L, Bergmann C, Gooding W, et al. 2007. The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin. Cancer Res. 13:6301-11
88. Wolf AM, Wolf D, Steurer M, et al. 2003. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res. 9:606-12
89. Lee SY, Choi HK, Lee KJ, et al. 2009. The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells. J. Immunother. 32:22-28
90. Pellegrini P, Berghella AM, Del Beato T, et al. 1996. Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol. Immunother. 42:1-8
91. Yao M, Kargman S, Lam EC, et al. 2003. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res. 63:586-92
92. Masferrer JL, LeahyKM, Koki AT, et al. 2000. Antiangiogenic and antitumor activities of cyclooxygenase- 2 inhibitors. Cancer Res. 60:1306-11
93. Oshima M, Dinchuk JE, Kargman SL, et al. 1996. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87:803-9
94. Williams CS, Tsujii M, Reese J, et al. 2000. Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Invest. 105:1589-94
95. SonoshitaM, Takaku K, Sasaki N, et al. 2001. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat. Med. 7:1048-51